Cytomegalovirus viral load parameters associated with earlier initiation of pre-emptive therapy after solid organ transplantation

被引:9
作者
Lumley, Sheila [1 ,5 ]
Green, Cameron [1 ]
Rafferty, Hannah [1 ]
Smith, Colette [2 ]
Harber, Mark [3 ]
O'Beirne, James [4 ,6 ]
Jones, Gareth [3 ]
Thorburn, Douglas [4 ]
Marshall, Aileen [4 ]
Shah, Tina [4 ]
Zuhair, Mohamed [1 ]
Rothwell, Emily [1 ]
Atabani, Sowsan [1 ,7 ]
Haque, Tanzina [1 ]
Griffiths, Paul [1 ]
机构
[1] UCL, Med Sch, Ctr Virol, London, England
[2] UCL, Inst Global Hlth, London, England
[3] Royal Free Hosp, Renal Transplant Unit, London, England
[4] Royal Free Hosp, Royal Free Sheila Sherlock Liver Ctr, London, England
[5] Oxford Univ Hosp NHS Fdn Trust, Oxford, England
[6] Sunshine Coast Univ Hosp, Birtinya, Qld, Australia
[7] Univ Hosp Birmingham, Natl Infect Serv, Publ Hlth England Birmingham Lab, Birmingham, W Midlands, England
来源
PLOS ONE | 2019年 / 14卷 / 01期
基金
英国惠康基金;
关键词
RECIPIENTS; KINETICS; DISEASE;
D O I
10.1371/journal.pone.0210420
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Human cytomegalovirus (HCMV) can be managed by monitoring HCMV DNA in the blood and giving valganciclovir when viral load exceeds a defined value. We hypothesised that such pre-emptive therapy should occur earlier than the standard 3000 genomes/ml (2520 IU/ml) when a seropositive donor transmitted virus to a seronegative recipient (D+R-) following solid organ transplantation (SOT). Methods Our local protocol was changed so that D+R-SOT patients commenced valganciclovir once the viral load exceeded 200 genomes/ml; 168 IU/ml (new protocol). The decision point remained at 3000 genomes/ml (old protocol) for the other two patient subgroups (D+R+, D-R+). Virological outcomes were assessed three years later, when 74 D+R- patients treated under the old protocol could be compared with 67 treated afterwards. The primary outcomes were changes in peak viral load, duration of viraemia and duration of treatment in the D+R-group. The secondary outcome was the proportion of D+R- patients who developed subsequent viraemia episodes. Findings In the D+R- patients, the median values of peak viral load (30,774 to 11,135 genomes/ml, p<0.0215) were significantly reduced on the new protocol compared to the old, but the duration of viraemia and duration of treatment were not. Early treatment increased subsequent episodes of viraemia from 33/58 (57%) to 36/49 (73%) of patients (p<0.0743) with a significant increase (p = 0.0072) in those episodes that required treatment (16/58; 27% versus 26/49; 53%). Median peak viral load increased significantly (2,103 to 3,934 genomes/ml, p<0.0249) in the D+R+ but not in the D-R+ patient subgroups. There was no change in duration of viraemia or duration of treatment for any patient subgroup. Interpretation Pre-emptive therapy initiated at the first sign of viraemia post-transplant significantly reduced the peak viral load but increased later episodes of viraemia, consistent with the hypothesis of reduced antigenic stimulation of the immune system.
引用
收藏
页数:11
相关论文
共 16 条
  • [1] [Anonymous], 2017, GUIDE MANAGING ETHIC
  • [2] [Anonymous], 2010, Collaborative study to evaluate the proposed 1st [first] WHO international standard for human cytomegalovirus (HCMV) for nucleic acid amplification (NAT)- based assays
  • [3] Cytomegalovirus Replication Kinetics in Solid Organ Transplant Recipients Managed by Preemptive Therapy
    Atabani, S. F.
    Smith, C.
    Atkinson, C.
    Aldridge, R. W.
    Rodriguez-Peralvarez, M.
    Rolando, N.
    Harber, M.
    Jones, G.
    O'Riordan, A.
    Burroughs, A. K.
    Thorburn, D.
    O'Beirne, J.
    Milne, R. S. B.
    Emery, V. C.
    Griffiths, P. D.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 (09) : 2457 - 2464
  • [4] Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation
    Cope, AV
    Sabin, C
    Burroughs, A
    Rolles, K
    Griffiths, PD
    Emery, VC
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (06) : 1484 - 1490
  • [5] Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation
    Emery, VC
    Sabin, CA
    Cope, AV
    Gor, D
    Hassan-Walker, AF
    Griffiths, PD
    [J]. LANCET, 2000, 355 (9220) : 2032 - 2036
  • [6] The dynamics of human cytomegalovirus replication in vivo
    Emery, VC
    Cope, AV
    Bowen, EF
    Gor, D
    Griffiths, PD
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (02) : 177 - 182
  • [7] Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients
    Fisher, Cynthia E.
    Knudsen, Janine L.
    Lease, Erika D.
    Jerome, Keith R.
    Rakita, Robert M.
    Boeckh, Michael
    Limaye, Ajit P.
    [J]. CLINICAL INFECTIOUS DISEASES, 2017, 65 (01) : 57 - 63
  • [8] Randomized Controlled Trials to Define Viral Load Thresholds for Cytomegalovirus Pre-Emptive Therapy
    Griffiths, Paul D.
    Rothwell, Emily
    Raza, Mohammed
    Wilmore, Stephanie
    Doyle, Tomas
    Harber, Mark
    O'Beirne, James
    Mackinnon, Stephen
    Jones, Gareth
    Thorburn, Douglas
    Mattes, Frank
    Nebbia, Gaia
    Atabani, Sowsan
    Smith, Colette
    Stanton, Anna
    Emery, Vincent C.
    [J]. PLOS ONE, 2016, 11 (09):
  • [9] Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial
    Griffiths, Paul D.
    Stanton, Anna
    McCarrell, Erin
    Smith, Colette
    Osman, Mohamed
    Harber, Mark
    Davenport, Andrew
    Jones, Gareth
    Wheeler, David C.
    O'Beirne, James
    Thorburn, Douglas
    Patch, David
    Atkinson, Claire E.
    Pichon, Sylvie
    Sweny, Paul
    Lanzman, Marisa
    Woodford, Elizabeth
    Rothwell, Emily
    Old, Natasha
    Kinyanjui, Ruth
    Haque, Tanzina
    Atabani, Sowsan
    Luck, Suzanne
    Prideaux, Steven
    Milne, Richard S. B.
    Emery, Vincent C.
    Burroughs, Andrew K.
    [J]. LANCET, 2011, 377 (9773) : 1256 - 1263
  • [10] The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients
    Humar, A.
    Lebranchu, Y.
    Vincenti, F.
    Blumberg, E. A.
    Punch, J. D.
    Limaye, A. P.
    Abramowicz, D.
    Jardine, A. G.
    Voulgari, A. T.
    Ives, J.
    Hauser, I. A.
    Peeters, P.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (05) : 1228 - 1237